Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

MMJ Recs

MAY 9, 2024

There are multiple US states with an established state-approved medical marijuana program as well as states permitting the use of cannabinol (CBD) oil – a non-psychoactive component of cannabis – for medical purposes exclusively.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

MARCH 1, 2022

Work with the Lead of Regulatory Affairs and the atai Development Team, and with moderate/minimal supervision, with select project teams within subsidiary organizations to develop and oversee program specific regulatory, clinical and development strategies. 5 years of hands-on regulatory experience.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. CBD Dosage Guidelines for Medical Use Determining the appropriate dosage of CBD for medical use is crucial to ensure optimal efficacy and safety.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Weedistry

FEBRUARY 4, 2019

Currently, 33 states along with the District of Columbia, Guam and Puerto Rico have passed laws for comprehensive medical cannabis programs — but critics often point out we’re lacking definitive proof that marijuana safely and effectively treats many of the qualifying conditions. There are two things wrong with this argument.

Clinical Trials 40

Clinical Trials Pharmaceutical Chronic Pain Safety 40

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Pain intensity and safety parameters were recorded on a 10-cm visual analogue scale (VAS) at pre-defined time points.

Chronic Pain 58

Chronic Pain Clinical Trials Marijuana Safety 58

MMJ Recs

JULY 9, 2024

States such as California, Colorado, and New York have established comprehensive medical marijuana programs with regulated dispensaries and patient registries. Some clinical trials have shown that cannabinoids, particularly THC and CBD, effectively reduce muscle spasticity and pain in MS patients.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

OCTOBER 2, 2021

Work with the Lead of Regulatory Affairs and the atai Development Team, and with moderate/minimal supervision, with select project teams within subsidiary organizations to develop and oversee program specific regulatory, clinical and development strategies. 5 years of hands-on regulatory experience.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

JULY 28, 2021

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. 2-3 years of relevant experience in clinical trials, research methods, or statistical design and analysis.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). About AIkido Pharma Inc.

Data 100

Data Research and Development Clinical Trials Therapy 100

NORML

JANUARY 4, 2019

Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution.

Legislation 123

Legislation Clinical Trials Research and Development Access 123

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Core Psilocybin Facilitation Skills (16 Hours).

Law 52

Law Programs Therapy Education 52

SpeedWeed

JULY 6, 2021

The Project on Psychedelics Law and Regulation (POPLAR) is a three-year project aiming to “promote safety, innovation, and equity in psychedelics research, commerce, and therapeutics,” the university said in a press release.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 23, 2022

SB 57 – which passed both houses – would have created a pilot program for overdose prevention sites in San Francisco, Oakland, and Los Angeles as an evidence-based intervention to curb drug overdose deaths. The continued criminalization of all drugs and the people who use them increases harms to public health and safety. ABOUT MAPS.

Decriminalization 52

Decriminalization Advocacy Research and Development Clinical Trials 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Miss Marijuana

JUNE 30, 2019

Miss Marijuana will break it down for you Bill Nye style so you can get back to your regularly scheduled program or go buy some CBD products! . Like a broken record we love to play, CBD research continues to find benefits in the cannabis product for chronic diseases, which then leads to better overall health and wellness! So what’s next?

Sleep 72

Sleep CBD Clinical Trials Oil 72

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

JULY 28, 2021

However, prior to committing to a substantial clinical program for that indication, PharmaDrug looked to further expand on the body of existing supportive data for esophageal cancer, while also potentially revealing new, promising cancer indications. ” Next Steps. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 5, 2021

Funders are endorsing MAPS’ mission and pursuit of mass mental health backed by 35 years of innovative leadership, governance, programs, and strategies. The safety and efficacy of MDMA-assisted therapy is currently under investigation. Interested prospective funders can submit their contact information here.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

JANUARY 13, 2020

In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JUNE 7, 2021

NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. Hurry, 917-733-5573, sanjay.hurry@adnas.com Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com Web: www.adnas.com Twitter: @APDN.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

NOVEMBER 26, 2021

With the anticipated launch of Pfizer’s oral COVID-19 antiviral drug candidate, Can-Fite has made a strategic decision to end its COVID-19 program and to focus its resources on its other clinical programs, all in advanced clinical trials. Fortified Balance Sheet. Financial Results. Forward-Looking Statements.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Veriheal

AUGUST 31, 2020

Program between St. About Sinibaldo: Sinibaldo is an aspiring healthcare professional and a biomedical researcher in the Medical Scientist Training Program (M.D./Ph.D.) About Nishtha: Nishtha is pursuing neurology to become a physician-scientist in honor of her grandmother Nani who suffered from Alzheimer’s.

Research and Development 117

Research and Development Education Agriculture Patients 117

The Joint Blog

DECEMBER 27, 2020

medical cannabis programs, the efficacy of dispensary-obtained cannabis needs to be thoroughly examined. medical cannabis programs, the efficacy of dispensary-obtained cannabis needs to be thoroughly examined.

Clinical Trials 49

Clinical Trials Marijuana Dispensary Treatment 49

Cannabis Law Report

MAY 1, 2022

The potential for OHA to deny or delay approval to entheogenic practitioners who apply for training program approval because they lack access to a licensed service center to satisfy the required practicum. Join Chacruna’s Studies in Psychedelic Justice Studies. OHA’s Authority to Regulate for Religious/Spiritual Use.

Safety 52

Safety History Programs Clinical Trials 52

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. . This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. ABOUT SANTÉ CANNABIS.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

OCTOBER 22, 2021

The THX-110 program takes a unique approach to cannabinoid formulation using the Entourage Effect hypothesis (i.e., Preclinical and Phase I clinical studies have demonstrated that VSN16R has the potential to provide substantially better patient care than existing systemic anti-spastic treatments. Key Questions Answered.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

The Cannigma

JULY 1, 2022

However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application. Non-clinical research can help answer questions regarding safety and risk in very powerful ways.

Research and Development 112

Research and Development Data THC Clinical Trials 112

Cannabis Law Report

OCTOBER 18, 2021

The THX-110 program takes a unique approach to cannabinoid formulation using the Entourage Effect hypothesis (i.e., Preclinical and Phase I clinical studies have demonstrated that VSN16R has the potential to provide substantially better patient care than existing systemic anti-spastic treatments. INM-755: InMed Pharmaceuticals.

Research and Development 52

Research and Development Pharmaceutical Chronic Pain Therapy 52

Cannabis Law Report

JUNE 4, 2021

In 1996, California legalized medical cannabis yet today, with 37 US States allowing for medical cannabis sales, we still do not have an overall comprehensive cannabis/cannabinoid education program. Based on the way it’s produced, Delta 8-THC should be batch tested to ensure consumer safety.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

The Joint Blog

OCTOBER 21, 2020

Due to the updated hemp act being relatively new, lawmakers are still studying and formulating policies that can better improve the industry while regulating it for the safety of users. Although scientific research on this has a long way to go, previous studies and clinical trials have produced promising results.

CBD 36

CBD Legalization Oil Hemp 36

Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

Clinical Trials 98

Clinical Trials Research and Development Hybrid Medicine 98

The Cannigma

JUNE 15, 2021

Families looking for the wonder plant started migrating to states with medical cannabis programs , becoming cannabis refugees, and their stories spread even further. . But the main issue with hemp derived products and their safety is less about the CBD and more about everything else in them. A multi-target panacea? What’s in your CBD?

CBD 122

CBD Research and Development Epilepsy Extraction 122

Puff Puff Post

DECEMBER 28, 2018

No single program or treatment is best, and specially tailored treatments based off the child’s needs are found to be most effective. The study also concludes that more clinical trials are required to take place before an accurate assessment on the use of cbd oil for autism can be made.

Treatment 76

Treatment Oil CBD Therapy 76